TABLE 1.
Baseline patient characteristics
| Demographics | sildenafil | controls | P value |
|---|---|---|---|
| Age (yrs) | 41.4 ± 3.4 | 45.4 ± 2.4 | 0.4 |
| Sex (F/M) | 13/1 | 13/1 | 0.5 |
| Height (cm) | 163 ± 2.6 | 165 ± 2.4 | 0.9 |
| Weight (kg) | 73 ± 5 | 72 ± 11 | 0.7 |
| Race | 0.5 | ||
| White (%) | 7 (50) | 5 (37) | |
| Hispanic (%) | 4 (29) | 3 (21) | |
| Asian (%) | 2 (14) | 6 (42) | |
| Black (%) | 1 (7) | 0 | |
| NYHA/WHO Class | 0.5 | ||
| II | 1 | 4 | |
| III | 11 | 9 | |
| IV | 2 | 1 | |
| Cause of pulmonary hypertension | 0.5 | ||
| Idiopathic (n) | 11 | 11 | |
| Associated with CTD (n) | 2 | 2 | |
| Corrected CHD (n) | 1 | 1 | |
| Resting haemodynamics | |||
| mRAP, mmHg | 9.1 ± 1.0 | 8.1 ± 0.9 | 0.4 |
| mPAP, mmHg | 50 ± 3.3 | 54 ± 4.3 | 0.4 |
| mPWP, mmHg | 10 ± 1.3 | 11 ± 1.1 | 0.9 |
| CO, L • min−1 | 3.9 ± 0.4 | 4.0 ± 0.4 | 1.0 |
| Cardiac Index, L • min−1• m² | 2.2 ± 0.2 | 2.2 ± 0.2 | 1.0 |
| PVR dyne•s•cm−5 | 901 ± 127 | 1048 ± 175 | 0.4 |
| mBP, mmHg | 91 ± 3 | 92 ± 4 | 0.7 |
| Background PAH therapy | 0.5 | ||
| prostacyclin analogue (n) | 6 | 7 | |
| endothelin antagonist (n) | 7 | 6 | |
| none (n) | 1 | 1 |
CTD = connective tissue disease; CHD = congenital heart disease